Praxis Precision Medicines, Inc. (PRAX) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGS. Market cap 7.36B USD. 52-week range 50.56 to 392.70 USD. Data as of 2026-10-09.
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small ...